Medindia

X

Biogen to Halt Development of Drug for Lou Gehrig’s Disease

by Kathy Jones on  January 4, 2013 at 7:59 PM Research News   - G J E 4
American pharmaceutical company Biogen Idec revealed that it will be stopping the development of its experimental drug to treat Lou Gehrig's disease after it failed to satisfy its primary target in the late-stage clinical trial.
 Biogen to Halt Development of Drug for Lou Gehrig’s Disease
Biogen to Halt Development of Drug for Lou Gehrig’s Disease
Advertisement

The company revealed that its drug, known as dexpramipexole, was unable to improve the survival period or slow down the loss of muscular function among patients with amyotrophic lateral sclerosis, or ALS. Currently there is no cure for the disease with just one drug approved, Sanofi's Rilutek, which is not too effective.

Advertisement
The ALS Association's spokeswoman, Carrie Martin Munk said that a number of people were hoping for the successful development of the drug and added that the association will be working closely with other companies to develop future drugs to treat the disease.

"There was a lot of hope behind this particular treatment. Other companies are presently developing treatments to help fight ALS, so while we are saddened by today's news and had obviously hoped for better results, we're going to keep working with companies to advance treatments and bring them to patients as soon as possible", Munk said.



Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All